



IPT

Immunosuppressant

lgcstandards.com/AXIO

ISO/IEC 17043 | ISO 9001



29821

IPT

Immunosuppressant

The LGC AXIO PT Immunosuppressant proficiency testing scheme provides independent performance assessment for laboratories performing quantification of immunosuppressant drugs in blood and plasma.

Immunosuppressant drugs are a class of drugs that suppress, or reduce, the strength of the body's immune system. In addition to being used to prevent organ rejection, they are often used to treat autoimmune disorders such as lupus, psoriasis, and rheumatoid arthritis.

Regular blood tests are essential for monitoring therapeutic levels and whether dosage changes are needed.

To successfully make these informed decisions laboratories need to demonstrate that drug measurements are reliable, reproducible and accurate.

The operation of the IPT scheme is supported by an Advisory Group consisting of members of the professional bodies, scheme participants, and others experienced in the field. The scheme reports on the performance of U.K. participants (who have clinical responsibilities) to the National Quality Assurance Advisory Panels for Chemical Pathology.

IPT

Immunosuppressant

Test Material*	Analyte*
Human blood	Ciclosporin/Tacrolimus, Everolimus, Sirolimus.
Plasma	Mycophenolic acid.

* The full range and availability of test materials and analytes is determined on an annual basis and may be added or removed. For accredited and non-accredited status please see current application form/scheme description.

